This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Quattrovac

Kaketsuken

Drug Names(s): Adsorbed Purified Pertussis Diphtheria Tetanus Inactivated Poliomyelitis (Sabin strain) Combined Vacc

Description: Quattrovac is a tetra-valent combined vaccine which includes the inactivated poliomyelitis vaccine derived from Sabin strains. The vaccine is made by combining the bulk materials of KAKETSUKEN’s approved Adsorbed Purified Pertussis Diptheria Tetanus Combined Vaccine (DPT vaccine) with the bulk of inactivated poliomyelitis vaccine derived from purified attenuated polio viruses (Sabin type 1, 2, and 3) cultured in Vero cells (a cell-line derived from African Green Monkey kidney cells) made by the Japan Poliomyelitis Research Institute (JPRI).

The vaccine is a 0.5 mL (1 syringe) injectable product which contains 4 units ormore of pertussis antigens, 16.7 Lf or less of diphtheria toxoid, 6.7 Lf or less oftetanus toxoid, 1.5 DU of type 1 (Sabin strain) inactivated polio virus, 50 DU oftype 2 (Sabin strain) inactivated polio virus, and 50 DU of type 3 (Sabin strain)inactivated polio virus as active ingredients.

Deal Structure: KAKETSUKEN and Astellas
The vaccine is manufactured at KAKETSUKEN. Astellas will conduct national sales and promotional activities similarly to its other vaccine and blood plasma products. Both companies will conduct joint sales promotion in the Kyushu area.

Partners: Astellas Pharma, Inc.


Quattrovac News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug